Next-generation gene therapy
Pioneering safe, non-immunogenic solutions for lasting therapeutic impact
Revolutionize autoimmune and inflammatory diseases treatment
THE NIMVEC™ ADVANTAGE
Nimvec™ is the only viral vector that can be re-dosed.
Nimvec™’s unique and superior properties include non-immunogenicity and capacity to induce immune tolerance without affecting the rest of the immune system.
Nimvec™ Therapeutics has developed a groundbreaking non-immunogenic viral platform to deliver transgenes of choice into humans. It is advancing a pipeline of transformative, potentially curative gene therapies for rare and prevalent diseases, including monogenetic, autoimmune and chronic inflammatory diseases.
Chronic Inflammation
Delivery of transgenes that
- downregulate drivers of inflammation and
- upregulate repair factors for long term immune balance
AUTOIMMUNITY
- Delivery of gene encoding primary self-antigen
- Induction of tolerance towards autoantigens (primary self-antigens and secondary autoantigens)
- Establish long term tolerance and immune homeostasis
Chronic Inflammation
Delivery of transgenes that
- downregulate drivers of inflammation and
- upregulate repair factors for long term immune balance
AUTOIMMUNITY
- Delivery of gene encoding primary self-antigen
- Induction of tolerance towards autoantigens (primary self-antigens and secondary autoantigens)
- Establish long term tolerance and immune homeostasis
We have developed a new non-immunogenic gene delivery vector platform named Nimvec™, derived from the macaque polyomavirus Simian Virus 40 (SV40). Replication-deficient SV40 vectors are highly effective in transducing a wide range of cell types and their therapeutic potential has been shown in animal models of human disease.
Since the virus strictly replicates in macaques, humans are immunologically naïve for SV40. In addition, it evades the human immune system and is therefore suitable for usage in tolerance induction, making SV40 vectors non-immunogenic and tolerogenic in humans and thereby constitute a highly attractive platform for use in gene and immunotherapies.
We have developed a new non-immunogenic gene delivery vector platform named Nimvec™, derived from the macaque polyomavirus Simian Virus 40 (SV40). Replication-deficient SV40 vectors are highly effective in transducing a wide range of cell types and their therapeutic potential has been shown in animal models of human disease.
Since the virus strictly replicates in macaques, humans are immunologically naïve for SV40. In addition, it evades the human immune system and is therefore suitable for usage in tolerance induction, making SV40 vectors non-immunogenic and tolerogenic in humans and thereby constitute a highly attractive platform for use in gene and immunotherapies.
SuperVero vector production cell line
We have constructed a safe and efficient vector production cell line named SuperVero, derived from the classical Vero cells that are routinely used for vaccine production. The Nimvec™ production process is robust, scalable and generic for different target genes, supporting the production of different therapeutics using the same process.
Safe, non-immunogenic gene delivery
Viral vector platform featuring immune tolerance induction and sustained transgene expression in humans
Safe, non-immunogenic gene delivery
Viral vector platform featuring immune tolerance induction and sustained transgene expression in humans
Broad therapeutic potential
Our platform targets fundamental mechanisms applicable to a broad range of autoimmune and inflammatory diseases
Type 1 Diabetes
Nimvec™ AM510 is a tolerance inducing gene therapy for the treatment of Type 1 Diabetes (T1D). T1D is an autoimmune disease in which self-reactive T lymphocytes attack and destroy insulin producing β-cells in the pancreas, leaving the patient unable to maintain glucose homeostasis. Proinsulin is considered to be the primary self-antigen involved in autoimmune β-cell destruction. AM510 delivers the gene for Proinsulin to the liver where its expression induces tolerance for this protein and halts further β-cell destruction.
Multiple Sclerosis
Nimvec™AMA003 is a tolerance inducing gene therapy for the treatment of Multiple Sclerosis. MS is an autoimmune disease in which self-reactive T lymphocytes attack and destroy oligodendrocytes leading to demyelination of axons in the brain and spinal cord, eventually resulting in functional disability and premature death.
Age-related Macular Degeneration
Nimvec™AMA004 is an anti-inflammatory, repair-promoting gene therapy vector for the treatment of patients with the dry form of Age-related Macular Degeneration (AMD). AMD is the main cause of irreversible impaired vision and blindness in elderly living in industrialized countries.
